Curetis AG, a developer of next-level molecular diagnostic solutions, has been granted a core technology patent by IP Australia, the Australian patent office, for its UnyveroTM platform technology. The patent, "Reaction Vessel for PCR Device and Method of Performing PCR," is the first of several core technology patents filed by Curetis. Its claims cover PCR chamber vessels allowing the integrated amplification and detection of DNA sequences. Curetis has submitted patent applications covering this technology in other key regions, including Europe, the U.S. and Japan. The Company expects these additional patents to be granted in the near future.
The CE-marked UnyveroTM System is a versatile hardware platform for the detection of a broad panel of bacteria, fungi and antibiotic resistances from a single sample in one run.
"We are extremely pleased that the patent was granted without any restrictions in scope, as it covers a critical and indispensable aspect of our Unyvero platform," said Dr. Gerd Luedke, Director Bio-Assay Development of Curetis. "This decision supports all of our claims around a unique and proprietary way of combining end-point PCR with an array-based detection in a single reaction vessel - something that has never been done before. It affords Unyvero certain competitive advantages in terms of multiplexing capabilities and cost of goods at a very high number of analytes."
"Our Unyvero Solution offers a highly attractive alternative to real-time PCR because it integrates both amplification and detection," said Oliver Schacht, CEO of Curetis. "Unyvero allows for superior multiplexing as compared to conventional PCR devices and methods without increasing the risk of sample cross-contamination."
Click here for the complete issue.